

PASPCR

Newsletter

Volume 3 Number 3

September, 1995

Introduction . . .

by the Publications Committee

The **PASPCR** *Newsletter* is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to the *Newsletter*; help us to update the Job Listings, Calendar of Events, Meeting Reports, Abstracts in press and other items of general membership interest. If you attend a scientific meeting at which you heard about work which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. If you should have a change of affiliation or address, we'd like to know that, too. This is **your** *Newsletter*, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to any of the members of the Publications Committee.

The Publications Committee wants to make collaboration between members of the Society as easy as possible and toward that goal we are encouraging the use of E-mail and other forms of electronic communications. We encourage everyone who has an E-mail address to forward it to the Publications Committee. The Publications Committee is willing to help any member of the PASPCR get you in touch with the individuals who can set up your E-mail account and to some extent will help you get started.

The **PASPCR** has a Gopher server that can be found from your home Gopher under "International Organizations" as "PanAmerican Society for Pigment Cell Research (PASPCR)". Here you have access to past PASPCR Newsletters, the current ByLaws and membership list. We are currently working with the IFPCS to develop a list of resources available to PASPCR members. This list will include cell lines, antibodies, coat color mutants and other items of interest to pigment researchers. If you have any other

IN THIS ISSUE Introduction PASPCR Contact Information Calendar of Events Welcome to New Members Corporate Sponsors 1995 PASPCR Elections 1996 XVI th Intl Pigment Cell Conf PASPCR Secretary/Treasurer's Report Meeting Report - Photobiology Members in the News Positions Wanted / Available INTERPIG Update Bibliography	p 1 p 2 p 3 p 3 p 3 p 3 p 3 p 5 p 6 p 6 p 7 p 15
enclosure: IFPCS DataBase Form	

ideas for items to be placed on Gopher, please contact someone on the Publications Committee.

PanAmerican Society for Pigment Cell Research

c/o Dr. Richard A. King

Department of Medicine University of Minnesota 516 Delaware St, SE Minneapolis, MN 55455 FAX: (612) 624-6645

Officers

Vincent J. Hearing President Sally Frost-Mason President-Elect Richard A. King Secretary/Treasurer

Council Members

Zalfa A. Abdel-Malek Raymond E. Boissy Murray H. Brilliant Alan N. Houghton Gert M. Jacobsohn William S. Oetting Seth J. Orlow Dewayne Townsend Walter C. Quevedo, Jr.

IFPCS Representative

James Nordlund Past-President

The **PASPCR Newsletter** is published quarterly; for further information and/or to submit articles, contact the: **Publications Committee:**

Dr. William S. Oetting (chair)

University of Minnesota 16-262 Moos Tower 515 Delaware St., S.E. Minneapolis, MN 55455-0311 FAX: (612) 626-4027 E-mail: BILL@LENTI.MED.UMN.EDU

Dr. Alan N. Houghton

Memorial Sloan-Kettering Cancer Center Chief, Clinical Immunology Service 1275 York Avenue New York, NY 10021 FAX: (212) 717-3036

Dr. Walter C. Quevedo, Jr.

Brown University Division of Biology and Medicine Box G Providence, RI 02912 FAX: (401) 863-1971

Calendar of Events :

- Oct 19 21, 1995 6th Meeting of the European Society for Pigment Cell Research, to be held in Lausanne, Switzerland (contact: ESPCR '95, Centre Pluridisciplaire d'Oncologie, CHUV-BH 06, CH-1011 Lausanne, Switzerland; FAX: +41 21/314-3957)
- Oct 27-28, 1995 Photocarcinogenesis: Mechanisms, Models and Human Health Implications, to be held in Washington DC (contact: Skin Diseases Research & Education Found, 23550 Commerce Park Road, Suite 2, Beachwood, OH 44122; FAX: 216/831-6385)
- Dec 2 3, 1995 Meeting of the Japanese Society for Pigment Cell Research, to be held in Osaka, Japan (contact: Prof. Toshiteru Morita, Dept of Biology, Osaka University, 560 Osaka, Japan; FAX: +81 6/850-5613)
- Dec 9 13, 1995 Annual Meeting of the American Society for Cell Biology, to be held in Washington DC (contact: ASCB National Office, 9650 Rockville Pike, Bethesda, MD 20814-3992; FAX: 301/530-7139)
- Oct 29- Nov 3, 1996 XVIth International Pigment Cell Conference, to be held in Anaheim, California, (contact: MMC/UCI Center for Health Education, PO Box 1428, Long Beach, CA 90801-1428, FAX: 310/933-2012)
- Jun 15-18, 1997 VIIth PASPCR Annual Meeting, to be held in Providence, RI (contact: Dr. Walter C Quevedo, Jr., Brown University, Division of Biology and Medicine, Providence, RI 02912; FAX: 401/863-1971)

----- 3 -----

Welcome to New Members

We welcome the following new members to the **PASPCR**

Edwart T. Borish Won Hyoung Kang Mark V. Reedy Ashok K. Chakrabotry Estela E. Medrano Michael Rachkovsky David Hewett-Emmett Kyoung Chan Park Stefano Sodi

If anyone is interested in joining our Society or wishes to sponsor a member, application forms can be obtained from Dr. Richard King at the PASPCR Secretary/Treasurer's office.

Corporate Sponsors

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons

ICN Pharmaceuticals, Inc Lawrence M Gelb Research Foundation of Clairol, Inc Ortho Pharmaceutical Corp

SILVER Corporate Patrons

Avon Products, Inc Chesebrough-Pond's USA Co Procter and Gamble Co Shiseido Co, Ltd

Corporate Patrons

Galderma Laboratories, Inc

1995 PASPCR Elections

The PASPCR will hold its annual elections at the end of this year. As announced at the General Business meeting held at the PASPCR Annual Meeting in Kansas City, the Nominations Committee has proposed a slate of candidates for the various open positions. We would like to remind the membership that additional names can be added to the ballot via the mechanism outlined in our ByLaws, i.e. by submitting a petition ballot signed by at least 5 active members of the Society and accompanied by a signed statement from the candidate that he/she is willing to run for that office. Such petition ballots must be delivered to the office of the Secretary/Treasurer (Dr. Richard King) no later than 2 months after the slate of candidates have been announced (i.e. by September 30, 1995). The Nominations Committee nominated several other individuals who have either declined to run or have not yet responded to an enquiry as to their interest in the position.

for President-Elect:	Richard A. King	
for Secretary/Treasurer:	James J. Nordlund	
for Council members:	Kenneth Mason Robert J. Smyth	David A. Norris John D. Taylor

XVIth IPCC (International Pigment Cell Conference)

by Roger Bowers, Frank Meyskens

The XVIth International Pigment Cell Conference will be held from October 29th to November 3rd, 1996 at the Disneyland Hotel in Anaheim, California. Frank Meyskens is the Organizer of this meeting

by Richard A King

by Richard A King

by Richard A King

with Roger Bowers and Alistair Cochran serving as co-chairs of the Organizing Committee. More information regarding this meeting (and its interesting venue) will be forthcoming in future Newsletters and in separate mailings. Dr. Meyskens has asked that the following announcements be included in our Newsletter.

- **Satellite Conferences**: No satellite conferences will be supported by the local organizing committee that are held within the time frame of the XVIth International Pigment Cell Conference, Tuesday, October 29, 1996; 6:00 pm to Sunday, November 3, 1996; 8:00 am. There are a wide number of venues possible to hold small or large satellite conferences either before or after the main pigment cell meeting. Our Memorial/UCI Educational Foundation will be happy to work with you in planning, for a small fee, and we request that we be notified of the intent of any satellite conference no later than June 1, 1995. If we are notified later than this date, accommodations and planning availability cannot be guaranteed.
- **Competitive Stipend for Travel Support**: The Organizing Committee will provide funds in a competitive manner for graduate students, post-doctoral fellows and those within five years of formal academic appointment. The number of stipends will depend on the availability of funds and further information will become available during the second and subsequent informational mailings.

PASPCR Secretary / Treasurer's Report :

by Richard A King

Following is a synopsis of the PASPCR Council Meeting held by teleconference on April 20, 1995 . . .

Hearing opened the meeting, and a quorum was declared present. Minutes of the January 19, 1995, Council meeting were unanimously approved. Total dues collected for 1995 has been \$10,315.

The Nominating Committee for the 1995 election will include Frost-Mason, Chair, Jacobsohn, (Council member) and R. Bowers, B. Fuller and A. Castrucci (Members-at-Large). The initial report of nominations will be made at the June meeting. The membership brochure was still in development and King was requested to circulate the final draft to the council for approval.

Quevedo reviewed the arrangements for the 1997 meeting in Providence. The meeting will be held at the Westin Hotel. The room cost will be \$115 per room for single or double occupancy. The Program Committee will be formed soon and the organizers were asked to consider a theme for the meeting so that potential keynote speakers can be identified. D. Norris has tentatively agreed to host the 1998 meeting in Denver.

Under old business, the amendment to the Young Investigator Award Rule and Regulation was discussed. Concern of excluding individuals who give good presentations at the annual meeting were reviewed, and it was suggested that the final list of nominations for the 1995 meeting be reviewed at the Council meeting in Kansas City. The Council can then decide whether it would be appropriate to return to the original procedure of having an anonymous committee select any eligible young investigator who presents at the meeting. This was accepted by the Council.

Fourteen travel award requests have been received for 1995. All requests will be reviewed and letters of acceptance sent to all individuals who meet the criteria of eligibility.

Under new business, Hearing reviewed the previous Rule and Regulation for Honorary Membership. Previous discussions by the Council had not addressed the issue of whether or not an Honorary Member should still be an active researcher and a member of Society. The Membership Committee was asked to review the Rule and Regulation on Honorary Membership and to develop several options that could deal with this issue. Hearing reviewed a letter from Frank Meyskens requesting the names of 3-5 members who are doing exciting new research, and 3-5 members who could serve as exciting participatory chairs of sessions. A committee that would identify individuals for this request was formed.

The minutes have been prepared by R. King, Secretary-Treasurer

----- 5 -----

Meeting Report :

by Helene Hill

Annual Meeting - American Society for Photobiology

June 17-22, Washington DC The ASP held its annual meeting in Washington, DC on June 17- 22, 1995 at the Hyatt Regency Capitol Hill Hotel. The weather was spectacular and we could sense the nation's heart beat as the days passed. Members of the press, legislators and others with a potential interest were invited to attend a pre-meeting workshop entitled What is Photobiology? organized by Frank Gasparro and held on Saturday, June 17. The session was well-attended in spite of weekend lure of the out-of-doors for Washington weekday shut-ins. Even veteran photoscientists had something to gain from this very stimulating session beamed at intelligent and educated laypersons. The workshop's success is reflected in the recent editorial in the Journal of the American Medical Association (August 9, 1995) entitled New Light on Skin Cancer Mechanisms by Charles Marwick. The article is summarized on our Web page which we invite all to visit (http://www/kumc.edu/ASP/pol_v01.htm).

Nik Kollias, well-known to the pigment cell world, organized a short course on Photodermatology along with Rox Anderson. This is a popular annual event which this year provided a critical update on the clinical status of photodynamic therapy in a number of skin conditions.

For us early risers (ugh) there was Photobiology School almost every morning at 8:00 AM. Topics covered included 'Carbenes and Nitrenes as Reagents for Photoaffinity Labeling Experiments' by Matthew Platz; 'Exclusion Studies: a Useful Technique for Assessing the Impact of Solar UV Radiation' by Donald Krizek; 'FDA Approval' by David Dolphin and 'The Possible Biological Effects of Electromagnetic Fields: A Review of Data and Concepts' by Jerry Williams.

Division meetings were held on the one morning without a school. The Society has subdivided itself into 5 sub-groups. These are 1.) Photochemistry, Photophysics and Phototechnology; 2.) Photosensory Biology; 3.) Photosynthesis and Photoconversion; 4.) Photomedicine; and 5.) Environmental Photobiology and UVR Effects. Each annual meeting is designed to have symposia, lectures, paper sessions, etc. that will be of interest to each division. Perspectives Lectures focus on each of the 5 divisions and are presented by eminent researchers in each field. Papers in our journal, Photochemistry and Photobiology, are grouped by Division. Pigment cell biologists who would like to join the ASP should have no trouble finding a suitable niche.

One of the most fascinating Symposia, entitled The Effects of UV-B Light on Natural Ecosystems, was organized by David Mitchell. The session dealt with such varied topics as photodamage in marine bacterioplankton, DNA damage in plants reared outdoors compared to indoors, the correlation of low photolyase with the decline of amphibian species and the genetic analysis of UVB-induced melanomas in Xiphophorine fish. Two interesting sessions were devoted to the Biomedical Effects of Ozone Loss and were organized by Thomas Coohill. Topics varied from measurement of UVB, immune suppression by UVB and assessment of sunscreens to consideration of the effect of increased UVB on phytoplankton. It is clear that there is much still to be learned in this important area.

Of particular interest to pigment cell researchers was the Symposium organized by Nik Kollias and Arthur Sober on UV-Induced Cutaneous Malignant Melanoma. Topics covered included epidemiology by Arthur Sober from whom we learned that about 2/3rds of melanomas worldwide are due to sunlight; hereditary melanoma by Ken Kraemer who demonstrated that lymphoblastoid cell lines from patients with familial malignant melanoma show abnormally high sensitivity to UVB mutagenesis; UV-induced melanomas in marsupials by Ron Ley who showed that the type of dietary fat can influence UV induction of melanoma; wavelength dependence of melanomas in fish by Dick Setlow who warned that conventional sunscreens by decreasing erythema with its action spectrum maximum in the UVB may actually lead to an increase in melanoma due to the disproportionate amount of UVA in sunlight and the enhanced sensitivity of melanomas to longer wave lengths. The

----- 6 -----

final talk was by Meenhard Herlyn who is well-known to the PASPCR and described a model for the study of UV transformation of human melanocytes.

Two ASP members were honored at the meeting. Jim Cleaver received the ASP Award and delivered a lecture on **Mending Human Genes**. Jim, as most already know, discovered the repair defect in xeroderma pigmentosum and has continued to do seminal work in this field ever since. The New Investigator Award went to Thomas Akmar whose award lecture was about the **Photoactive Mechanism of Rhodopsin**.

Of special interest to women and minorities was the Forum which met at noon on Monday, June 19. While all ASP members are invited, the Forum is a gathering where women and minorities can discuss their problems, share experiences and meet and get to know each other. This past year we have produced a register which we hope to circulate to interested parties such as potential employers, organizers of study sections, meetings, review groups, etc. We hope in this manner to get more women and minorities into leadership roles in the Society and in the outside world, as well. At our next annual meeting, we hope to sponsor an eminent female or minority speaker who will not only present good science but will also spend some time talking about the road she/he traveled to arrive where she/he is today. Many young women and minorities feel shy and lonely at national meetings. We hope next year to have a gathering place for people who don't know many others to meet to go to lunch or dinner together. There will, of course, be no restrictions on who participates (i.e. men and majorities are also welcome). This should be especially helpful to students and post-docs.

Next year, the Society will meet in Atlanta, GA on June 15 - 19, 1996. Information about the meeting can be found on our Web page or may be obtained by calling, writing, or faxing to the Secretariat: Dr. Sherwood M. Reichard, 1021 15th Street, Suite 9, Augusta, GA 30901. Tel: 706-722-7511; fax: 706-721-3048. Zalfa Abdel-Malek and I are organizing a Symposium on Melanin Photobiology that will be co-sponsored by the ASP and the PASPCR. It will focus on photoprotection versus photosensitization. If anyone would like to suggest relevant topics and/or speakers (self-nomination is allowed) please let one of us know. On that same subject, I am organizing a Symposium-in-Print to appear in **Photochemistry and Photobiology** some time next year. If anyone would be interested in submitting a manuscript to me, please either do so or let me know of your intent. I would like to have all of the manuscripts in by the end of the year.

Members in the News

- Maher Haddad received a Young Investigator Award at the PASPCR Annual Meeting in Kansas City.
- William Oetting received a Young Investigator Award at the PASPCR Annual Meeting in Kansas City.

Scott Wildenberg received a Young Investigator Award at the PASPCR Annual Meeting in Kansas City.

Positions - Wanted and Available :

Aaron Lerner was awarded the PASPCR Career Achievement Award for 1996; it was presented to him during the PASPCR Annual Meeting held in Kansas City.

Predoctoral Position - Opportunity available to do graduate studies towards a doctoral degree at the University of Cincinnati College of Medicine. Graduate program is through the Department of Cell Biology, Neurobiology, & Anatomy. Dissertation project would focus on molecular biology of the melanocyte physiology and pigmentary diseases. For information contact: Raymond E. Boissy, Ph.D., Department of Dermatology, University of Cincinnati College of Medicine, 231 Bethesda Avenue ML-592, Cincinnati, Ohio 45267-0592; (513)558-6242 [TEL]; (513)558-0198 [FAX]; boissyre@ucbeh.san.uc.edu [eMAIL].

- **Faculty Position** Massachusetts General Hospital, Harvard Medical School, Cutaneous Biology Research Center. The Cutaneous Biology Research Center (CBRC) seeks a molecular, cellular or developmental biologist to establish a program in fundamental research relevant to skin pigmentation. Areas of reseearch can include but are not limited to pigment synthesis and transfer in melanocytes, genetics of mouse coat color and development/migration of neural crest cells. Applicants must have a Ph.D. and/or M.D. degree and relevant postdoctoral experience. Only applicants with a strong research record and the potential to develop extramurally supported research programs will be considered. Individuals with a demonstrated ability to develop imaginative approaches to important biological questions are particularly encouraged to apply. Rank/salary/start-up funds and space are negotiable depending on experience and qualifications. The CBRC occupies 45,000 square feet of fully equipped laboratory space in a new multidisciplinary research facility. Interested individuals should send curriculum vitae, reprints, a statement of research and future directions, along with the names, addresses and telephone numbers of three references to: Dr. Paul F. Goetinck, Chair, Faculty Search Committee, Cutaneous Biology Research Center, Massachusetts General Hospital - East, Building 149, 13th Street, Charlestown, MA 02129
- **Director, Section of Basic Science Research -** the Department of Dermatology and the Research Institute of the Cleveland Clinic Foundation are seeking applications for a full-time research scientist. Candidates should possess an M.D. and/or Ph.D. degree and have research experience in one of the following areas: wound healing, keratin/collagen biochemistry, or cancer immunology/molecular biology. The successful candidate will have the ability to work as an independent investigator and be the focus for dermatological research in a dynamic, multi-disciplinary and supportive environment. Preference will be given to individuals who have demonstrated prior success in obtaining extramural support. Salary and title will be commensurate with training and experience. A University affiliation is available. Send C.V. to: Charles Camisa, M.D., Vice-Chair, Department of Dermatology, A61, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195-5032.

INTERPIG DataBase

by Vincent Hearing

The INTERPIG database is underway! Following is the current listing of supplies and suppliers that have been entered int the database. Please note that as of this time, only 4 PASPCR members have contributed entries (this represents only about 3% of our membership). Think of how useful and complete this list would be if everyone took the time to supply their own information. Please take a moment to fill out the database data entry form and send it back to Dr. Hearing (a copy of the entry form is inserted into this Newletter, and it can be photocopied).

IFPCS DataBase

Base Supplie

Supplies and Suppliers Summary (current as of: February 13, 2008)

<u>Category</u>	<u># Entries</u>	<u>Society</u>	<u># contributors</u>
Animals :	35	ESPCR :	10
Biochemical/Chemical :	17	JSPCR :	0
Cell Culture :	7	PASPCR :	4
Dermatology/Clinical :	0		
Immunology :	11		
Molecular Biology :	0		
Other :	0		

Full Name: Dr. Dorothy Bennett (3) Institution: St. George's Hospital Medical School Department: Department of Anatomy Building/Room: University of London Street Address: Cranmer Terrace, Tooting City: London Postal Code: SW 17 Country: United Kingdom Work Phone: 44-81-725-5202 Fax Number: 44-81-725-3326 **Email Address:** ESPCR: X Nonprofit: X Full Name: Christopher John Cooksey (6) Institution: University College London Department: Department of Chemistry Building/Room: Room 428 Street Address: 20 Gordon Street City: London Postal Code: WC1H OAJ Country: United Kingdom Work Phone: 44-171-380-7777-4694 Fax Number: 44-171-380-7463 Email Address: ucca54c@ucl.ac.uk ESPCR: X Nonprofit: X Full Name: Dr. Mary K. Cullen (1) Institution: Washington University School of Medicine Department: Dept of Cell Biology and Physiology Building/Room: Box #8228 Street Address: 660 S. Euclid Street City: St. Louis State/Province: Missouri Postal Code: 63110 Country: USA Work Phone: 01-314-362-1082 Fax Number: 01-314-362-7463 Email Address: mkcullen@cellbio.wash.edu PASPCR: X Nonprofit: X Full Name: Drs. Eric Donois & Jean-Etienne (1) Surlève-Bazeille Institution: Université Bordeaux I **Department:** Dépt de Microscopie Electronique **Street Address:** 351, Cours de la Libération **City:** Talence Postal Code: 33405 Talence Cedex Country: France Work Phone: 33-56-84-63-88 Fax Number: 33-56-84-66-70 **Email Address:** ESPCR: X Nonprofit: X (5) Full Name: Dr. Vincent J Hearing **Institution:** National Institutes of Health **Department:** Laboratory of Cell Biology **Building/Room:** Building 37 Room 1B25 Street Address: 9000 Rockville Pike City: Bethesda State/Province: MD ----- 9 -----

Postal Code: 20892 Country: USA Work Phone: 01-301-496-1564 Fax Number: 01-301-402-8787 Email Address: hearingv@dc37a.nci.nih.gov ESPCR: X PASPCR: X Nonprofit: X Full Name: Prof. Kowichi Jimbow Institution: University of Alberta (7) Department: Department of Dermatology & Cutaneous Sciences Building/Room: 260G Heritage Medical Research Center City: Edmonton State/Province: Alberta Postal Code: T5K OH2 Country: Canada Work Phone: 01-403-492-2425 Fax Number: 01-403-492-7715 Email Address: kjimbow@gpu.srv.ualberta.ca PASPCR: X Nonprofit: X (35) Full Name: Dr. M. Lynn Lamoreux Institution: Texas A & M University Department: Dept of Veterinary Pathobiology City: College Station State/Province: TX Postal Code: 77843 Country: USA Work Phone: 01-409-845-6084 Fax Number: 01-409-845-9972 Email Address: llamoreux@vetmed.tamu.edu PASPCR: X Nonprofit: X (1) Full Name: Dr. Anna Palumbo Institution: Stazione Zoologica Street Address: Villa Communale City: Naples Postal Code: 80121 Country: Italy Work Phone: 39-81-583-3276 Fax Number: 39-81-764-1355 **Email Address:** ESPCR: X Nonprofit: X Full Name: Prof. Dr. Martn G. Peter (1) Institution: Universitaet Potsdam Department: Department of Organische Chemie Building/Room: Haus 9 Street Address: Am Neuen Palais 10 City: Potsdam Postal Code: D-14469 Country: Germany Work Phone: 49-331-977-1450 Fax Number: 49-331-977-1131 Email Address: peter@serv.chem.uni-potsdam.de ESPCR: X Nonprofit: X

Full Name: Dr. Ralf U. Peter

(1)

Institution: University of Munich Department: Department of Dermatology Street Address: Frauenlobstrasse 9-11 City: Munich State/Province: Bavaria Postal Code: 80337 Country: Germany Work Phone: 49-89-3168-3897 Fax Number: 49-89-5160-4527 Email Address: ESPCR: X Nonprofit: X

Full Name:Prof. Giuseppe Prota(5)Institution:University of NaplesDepartment:Dept of Organic & Biological ChemStreet Address:Mezzocannone 16City:NaplesPostal Code:80134Country:ItalyWork Phone:39-81-704-1249Fax Number:39-81-552-1217Email Address:ESPCR:XNonprofit:

Full Name: Prof. Patrick A. Riley Institution: UCL Medical School Department: Department of Molecular Pathology Building/Room: Windeyer Building Street Address: Cleveland Street City: London Postal Code: W1P 6DB Country: United Kingdom Work Phone: 44-171-380-9323 Fax Number: 44-171-637-4436 Email Address: rebc900@ucl.ac.uk ESPCR: X Nonprofit: X (2)

Full Name: Dr. Maria Anna Rosei Institution: University La Sapienza Department: Department of Biochemical Sciences Street Address: Piazza A. Moro, 5 City: Rome Postal Code: 00185 Country: Italy Work Phone: 39-6-4991-0923 Fax Number: 39-6-4440-062 Email Address: ESPCR: X Nonprofit: X

Full Name: Dr. Alain Taieb Institution: University of Bordeaux 2 Department: Department of Dermatology Building/Room: 1B, Carreire Nord Street Address: 146, Rue led Saignat City: Bordeaux Postal Code: 33076 Country: France Work Phone: 33-56-79-56-22 Fax Number: 33-56-79-59-87 Email Address: ESPCR: X Nonprofit: X (2)

----- 10 -----

Animals (35)

Item: C57BL/6J-c^{2J}/c^{2J} B/B **Description:** albino black mice Method: animals Quantity: upon request **Réference**: Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: C57BL/6J-c^{2J}/c^{2J} b/b Description: albino brown mice **Method:** animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-c^{ch}/c^{ch} B/B Description: chinchilla black mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J- $c^{ch}/c^{ch}b/b$ Description: chinchilla brown mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: C57BL/6J-c^p/c^p Description: platinum mice Method: animals Quantity: upon request **Réference**: Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-c^a/c^a Description: acromelanic mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-ch/ch **Description:** himalayan mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-c^{em}/c^{em} Description: extreme dilution mottled mice **Method:** animals

Quantity: upon request

Reference: Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux **Item:** C57BL/6J-c^m/c^m **Description:** mottled mice Method: animals Quantity: upon request **Reference: Comment:** must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: c^{6H}/c^{ch} Description: albino mice Method: animals Quantity: upon request **Reference: Comment:** must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: c^{14CoS}/c^{ch} Description: albino mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J Description: black mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-p^{un}/p^{un} Description: pinkeyed unstable mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-slt/slt Description: slaty mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: fd/fd Description: faded mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux

Item: si/si

----- 11 -----

Description: silver mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: C57BL/6J-Mi^{wh}/mi **Description:** microphthalmia mice **Method:** animals Quantity: upon request **Réference**: Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-Mi^{wh}/mi^{sp} Description: microphthalmia mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: mirw/mivit **Description:** microphthalmia mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: miws/miws Description: microphthalmia mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: Mi^{OR}/mi^{vit} Description: microphthalmia mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: mi^{ce}/mi^{vit} Description: microphthalmia mice **Method:** animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: mivit/mivit Description: microphthalmia mice **Method:** animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs

Source: Dr. M. Lynn Lamoreux Item: Description: belted mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-W^{J2}/+ Description: Jay's dominant spotting mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: ls/ls **Description:** lethal spotting mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: Ju/FcCtLm-c+c+ Rw/+ **Description:** Rump white mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: C57BL/6J-Ay/a Description: lethal yellow mice Method: animals Quantity: upon request **Reference: Comment:** must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: C57BL/6J-A^y/a b/b **Description:** lethal yellow, brown mice Method: animals Quantity: upon request **Réference**: **Comment:** must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-Ay/a mg/mg Description: lethal yellow, mahogany mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: JU/FcCtLm Ay/a Description: lethal yellow mice Method: animals Quantity: upon request

----- 12 -----

Reference: Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux **Item:** C57BL/6J-a^m/a^m **Description:** nonagouti mottled mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs **Source:** Dr. M. Lynn Lamoreux Item: JU/FcCTLm-a^m/a^m Description: nonagouti mottled mice Method: animals Quantity: upon request **Reference: Comment:** must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-e/e Description: recessive yellow mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Item: C57BL/6J-E^{so}/E^{so} Description: sombre mice Method: animals Quantity: upon request **Reference:** Comment: must order in advance - \$25 service charge plus shipping costs Source: Dr. M. Lynn Lamoreux Biochemicals / Chemicals (17) Item: catecholamines Description: labeled compounds, stable isotopes **Method:** chemistry Quantity: upon request **Reference:** Liebigs Annalen der chemie, 563-567, 1994 Comment: Source: Prof. Dr. Martn G. Peter Item: Quantimel Program

Description: stereological image analysis for quantitation of melanization Method: electron microscopy Quantity: Reference: Comment: tool for the estimation of the melanin and melanosome content, especially for cultured cells Source: Drs. Eric Donois & Jean-Etienne Surlève-Bazeille

Item: opiomelanins Description: soluble melanins from opioid peptides Method: biochemistry Quantity:

Reference: Biochim Biophys Acta 1199:123-129, 1994 **Comment:** Source: Dr. Maria Anna Rosei Item: PTCA Description: standardized solution for HPLC Method: chemistry Quantity: 5-10 µg/ml **Reference:** Comment: prepared by degradation of DHICA with alkaline H₂O₂ Source: Prof. Giuseppe Prota Item: DOPA melanin **Description:** black powder, equilibrated on saturated CaCl₂ Method: chemistry Quantity: 10-50 mg **Reference:** Gazz Chim Ital 123:241-242, 1993 **Comment:** tyrosinase catalyzed oxidation of DOPA / pH 7.0, 25 C, 2.5 hr **Source:** Prof. Giuseppe Prota Item: DHICA melanin(s) Description: black powder Method: chemistry Quantity: 5-10 mg Reference: Comment: prepared by enzymic oxidation of DHICA Source: Prof. Giuseppe Prota **Item:** DHI melanin(s) **Description:** black powder Method: chemistry Quantity: 5-10 mg **Reference:** Comment: prepared by enzymic oxidation of DHI Source: Prof. Giuseppe Prota Item: 5-S-cysteinylDOPA Description: white crystalline powder Method: chemistry Quantity: 5 mg Reference: Synth Commun 16:967-971, 1986 Comment: prepared by chemical oxidation of DOPA Source: Prof. Giuseppe Prota Item: sepiomelanin Description: black powder hygroscopic Method: chemistry Quantity: 50 mg **Reference:** Comment: prepared by centrifugation of the fresh ink of Sepia, dried over silica gel and equilibrated in CaCl₂ Source: Dr. Anna Palumbo Item: KUI/1 Description: 4-methoxyphenyl-1alpha(D)mannopyranoside (KUI) Method: biochemistry Quantity: 10 mg Reference: Melanoma Res 1:273-287, 1991 Comment: tyrosinase analogue substrate XXII Source: Prof. Patrick A. Riley

---- 13 -----

Item: KUI/2 **Description:** 4-methoxyphenyl- $1\beta(D)$ glucopyranoside (KÚI) Method: biochemistry Quantity: 10 mg Reference: Melanoma Res 1:273-287, 1991 Comment: tyrosinase analogue substrate XXIII Source: Prof. Patrick A. Riley Item: 4-propoxyphenol **Description:** substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 10 mg Reference: Melanoma Res 1:273-287, 1991 **Comment:** tyrosinase analogue Source: Christopher John Cooksey Item: 4-(2-hydroxyethylthio)phenol Description: substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 10 mg Reference: Melanoma Res 1:273-287, 1991 **Comment:** tyrosinase analogue **Source:** Christopher John Cooksey Item: 4-(2-hydroxyethoxy)phenol Description: substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 10 mg Reference: Melanoma Res 1:273-287, 1991 **Comment:** tyrosinase analogue Source: Christopher John Cooksey Item: 4-isobutoxyphenol Description: substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 10 mg **Reference:** Melanoma Res 1:273-287, 1991 **Comment:** tyrosinase analogue Source: Christopher John Cooksey Item: 4(2-bromoethoxy)phenol Description: substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 10 mg **Reference:** Melanoma Res 1:273-287, 1991 **Comment:** tyrosinase analogue Source: Christopher John Cooksey Item: 4-(2thioethylthio)phenol Description: substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 10 mg **Reference:** Melanoma Res 1:273-287, 1991 **Comment:** tyrosinase analogue **Source:** Christopher John Cooksey Item: N-acetyl-4-S-cysteaminylphenol Description: substituted phenol substrate for tyrosinase Method: biochemistry Quantity: 5 mg **Reference:** Cancer Res 50:3743-3747, 1990

Cell Culture (7) Item: melan-a cells Description: black C57BL/6 murine melanocyte line Method: cell culture Quantity: 1 ml Reference: Int. J. Cancer 39:414-418, 1987 **Comment:** immortalized from a C57Bl/6 mouse Source: Dr. Dorothy Bennett **Item:** melan-b cells **Description:** brown (b/b) murine melanocyte line Method: cell culture Quantity: 1 ml Reference: Development 105:379-385, 1989 **Comment:** immortalized from a b/b mouse of Falconer's Q-strain Source: Dr. Dorothy Bennett **Item:** melan-c cells **Description:** albino (c/c) murine melanocyte line **Method:** cell culture Quantity: 1 ml Reference: Development 105:379-385, 1989 **Comment:** immortalized from partially-outbred LAC-MF1 Swiss mice Source: Dr. Dorothy Bennett **Item:** reconstructed epidermis **Description:** with melanocytes Method: cell culture Quantity: Reference: Pigment Cell Res (in press), 1995 Comment: allows pharmacological and pathophysiologic studies Source: Dr. Alain Taieb **Item:** melanocyte culture Description: without phorbol esters and cAMP agonists Method: cell culture Quantity: **Reference:** Arch Dermatol Res 285:385-392, 1993 **Comment:** allows physiological assays on melanocytes ex vivo Source: Dr. Alain Taieb Item: Irradiated melanoma cells Description: human cell lines irradiated (240 kV) Xray Method: cell culture **Quantity:** 10⁸ cells **Reference:** Comment: a system to study increased tyrosine kinase expression Source: Dr. Ralf U. Peter Item: Neonatal human melanocytes Description: black, caucasian or mixed - primary culture Method: tissue culture Quantity: 2x10⁶ cells Reference: J. Invest. Dermatol. 97:395-404, 1991

Comment: tyrosinase substrate

Source: Prof. Kowichi Jimbow

----- 14 -----

Comment: will supply only investigators without access to human skin, or who have lost their primary culture lines **Source:** Dr. Mary K. Cullen

Dermatology / Clinical (0)

Immunology (11)

Item: α-PEP1 **Description:** TRP1 antibody Method: immunology Quantity: 1 ml **Reference:** J Biol Chem 264:3397-3403, 1989 **Comment:** recognizes mouse, but not human **Source:** Dr. Vincent J Hearing **Item:** α-PEP7 **Description:** tyrosinase antibody Method: immunology Quantity: 1 ml Reference: J Biol Chem 266:1147-1156, 1991 Comment: recognizes mouse and human (weakly) Source: Dr. Vincent J Hearing Item: α-PEP8 Description: TRP2 antibody Method: immunology Quantity: 1 ml **Reference:** EMBO J 11:519-526, 1992 **Comment:** recognizes mouse and human **Source:** Dr. Vincent J Hearing **Item:** α-PEP13 **Description:** silver antibody Method: immunology Quantity: 1 ml Reference: J Biol Chem 269:29198-29205, 1994 **Comment:** recognizes mouse and human **Source:** Dr. Vincent J Hearing Item: α -PEP5 **Description:** tyrosinase antibody Method: immunology **Quantity:** 1 ml **Reference:** J Biol Chem 266:1147-1156, 1991 Comment: recognizes mouse and human (strongly) if denatured Source: Dr. Vincent J Hearing Item: HMSA-1 Description: MoAb to human melanosome specific antigen - 1, mouse IgG1 k Method: immunology Quantity: 0.5 ml Reference: J Invest Dermatol 100:259S-268S, 1993 Comment: these antibodies can also be used for routine paraffin sections **Source:** Prof. Kowichi Jimbow Item: HMSA-2 Description: MoAb to human melanosome specific antigen - 2, mouse IgG1 k Method: immunology Quantity: 0.5 ml Reference: J Invest Dermatol 100:259S-268S, 1993

Comment: these antibodies can also be used for routine paraffin sections Source: Prof. Kowichi Jimbow Item: HMSA-3 Description: MoAb to human melanosome specific antigen - 3, mouse IgM k Method: immunology Quantity: 0.5 ml **Reference:** J Invest Dermatol 100:259S-268S, 1993 Comment: these antibodies can also be used for routine paraffin sections **Source:** Prof. Kowichi Jimbow Item: HMSA-4 Description: MoAb to human melanosome specific antigen - 4, mouse IgM k Method: immunology Quantity: 0.5 ml Reference: J Invest Dermatol 100:259S-268S, 1993 Comment: these antibodies can also be used for routine paraffin sections Source: Prof. Kowichi Jimbow Item: HMSA-5 Description: MoAb to human melanosome specific antigen - 5, mouse IgG1 k Method: immunology Quantity: 0.5 ml Reference: J Invest Dermatol 100:259S-268S, 1993 Comment: these antibodies can also be used for routine paraffin sections **Source:** Prof. Kowichi Jimbow Item: HMSA-7 Description: MoAb to human melanosome specific antigen - 7, mouse IgG1, k Method: immunology Quantity: 0.5 ml Reference: Melanoma Res 3:331-335, 1993 Comment: these antibodies can also be used for routine paraffin sections Source: Prof. Kowichi Jimbow

Molecular Biology (0)

<u>Other (0)</u>

Bibliography :

The Bibliography published in this issue covers the period February, 1995 through April, 1995. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. We have attempted to highlight any publications which include a member of the PASPCR with a star.

MELANINS, MELANOGENS & MELANOGENESIS

- Alena F, Dixon W, Thomas P, Jimbow K: Glutathione plays a key role in the depigmenting and melanocytotoxic action of N-acetyl-4-S-cysteaminylphenol in black and yellow hair follicles. J Invest Dermatol 104:792-797 (1995).
- Ando H, Itoh A, Mishima Y, Ichihashi M: Correlation between the number of melanosomes, tyrosinase mRNA levels, and tyrosinase activity in cultured murine melanoma cells in response to various melanogenesis regulatory agents. J Cell Physiol 163:608-614 (1995).
 - Archambault M, Yaar M, Gilchrest BA: Keratinocytes and fibroblasts in a human skin equivalent model enhance melanocyte survival and melanin synthesis after ultraviolet irradiation. J Invest Dermatol 104:859-867 (1995).
 - Blasi E, Barluzzi R, Mazzolla R, Tancini B, Saleppico S, Puliti M, Pitzurra L, Bistoni F: Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol 58:111-116 (1995).
 - Bluetpajot MT, Presse F, Voko Z, Hoeger C, Mounier F, Epelbaum J, Nahon JL: Neuropeptide-E-I antagonizes the action of melanin-concentrating hormone on stress-induced release of adrenocorticotropin in the rat. J Neuroendocrinol 7:297-303 (1995).
 - Bora NS, Kim MC, Kabeer NH, Simpson SC, Tandhasetti MT, Cirrito TP, Kaplan AD, Kaplan HJ: Experimental autoimmune anterior uveitis - Induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Visual Sci 36:1056-1066 (1995).
 - Caesartonthat TC, Kloeke FV, Geesey GG, Henson JM: Melanin production by a filamentous soil fungus in response to copper and localization of copper sulfide by sulfide-silver staining. Appl Environ Microbiol 61:1968-1975 (1995).
 - Clarke CE: Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Movement Disord 10:250-256 (1995).
 - Depotter P, Shields CL, Shields JA, Flanders AE: Does the melanin content of uveal malignant melanomas correlate with their magnetic resonance imaging appearance? In reply. Arch Ophthalmol 113:556(1995).
 - Duttlinger R, Manova K, Berrozpe G, Chu TY, Deleon V, Timokhina I, Chaganti RSK, Zelenetz AD, Bachvarova RF, Besmer P: The W-sh and Ph mutations affect the c-kit expression profile: C-kit misexpression in embryogenesis impairs melanogenesis in W-sh and Ph mutant mice. Proc Natl Acad Sci USA 92:3754-3758 (1995)
- Farooqui JZ, Robb E, Boyce ST, Warden GD, Nordlund JJ: Isolation of a unique melanogenic inhibitor from human skin xenografts: Initial *in vitro* and *in vivo* characterization. J Invest Dermatol 104:739-743 (1995).
- Ferris J, Bloom P: Does the melanin content of uveal malignant melanomas correlate with their magnetic resonance imaging appearance? Arch Ophthalmol 113:555-556 (1995). Foss AJE, Alexander RA, Jefferies LW, Lightman S: Immunohistochemical techniques: The effect of melanin
- bleaching. Brit J Biomed Sci 52:22-25 (1995).
- Hiruma K, Carter MS, Riddiford LM: Characterization of the dopa decarboxylase gene of *Manduca sexta* and its suppression by 20-hydroxyecdysone. Dev Biol 169:195-209 (1995).
- Hu DN, Mccormick SA, Orlow SJ, Rosemblat S, Lin AY, Wo K: Melanogenesis by human uveal melanocytes in vitro. Invest Ophthalmol Visual Sci 36:931-938 (1995).
- Kageura H, Eguchi G, Yamana K: The origin and development of retinal pigment cells and melanophores analyzed by *Xenopus* black-white chimeras. Dev Growth Differ 37:157-166 (1995).
- Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ: The expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2), the silver protein, and a melanogenic ø inhibitor in human melanoma cells of differing melanogenic activities. Pigm Cell Res 8:97-104 (1995).
- Kobayashi T, Vieira WD, Potterf B, Sakai C, Imokawa G, Hearing VJ: Modulation of melanogenic protein expression during the switch from eu- to pheomelanogenesis. J Cell Sci 108:2301-2309 (1995).
- Korytowski W, Sarna T, Zareba M: Antioxidant action of neuromelanin: The mechanism of inhibitory effect on lipid peroxidation. Arch Biochem Biophys 319:142-148 (1995).
- Kotob SI, Coon SL, Quintero EJ, Weiner RM: Homogentisic acid is the primary precursor of melanin synthesis in Vibrio cholerae, a Hyphomonas strain, and Shewanella colwelliana. Appl Environ Microbiol 61:1620-1622 (1995).
- Kuwabara H, Cumming P, Yasuhara Y, Leger GC, Guttman M, Diksic M, Evans AC, Gjedde A: Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nucl Med 36:1226-1231 (1995).
- Martinez-Liarte JH, Solano F, Lozano JA: Effect of penicillin-streptomycin and other antibiotics on melanogenic parameters in cultured B16/F10 melanoma cells. Pigm Cell Res 8:83-88 (1995).

- Mimaki Y, Kameyama A, Sashida Y, Miyata Y, Fujii A: A novel hexahydrodibenzofuran derivative with potent inhibitory activity on melanin biosynthesis of cultured B- 16 melanoma cells from Lindera umbellata bark. Chem Pharm Bull Tokyo 43:893-895 (1995).
- Misu Y, Ueda H, Goshima Y: Neurotransmitter-like actions of L-DOPA. Advances in Pharmacology, Vol 32:427-459 (1995)
- Napolitano A, Crescenzi O, Pezzella A, Prota G: Generation of the neurotoxin 6-hydroxydopamine by peroxidase H_2O_2 oxidation of dopamine. J Med Chem 38:917-922 (1995).
- Napolitano A, Pezzela A, Vincensi MR, Prota G: Oxidative degradation of melanins to pyrrole acids: A model study. Tetrahedron 51:5913-5920 (1995).
- Opackajuffry J, Brooks DJ: L-dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. Movement Disord 10:241-249 (1995).
- Pierce JA, Rast DM: A comparison of native and synthetic mushroom melanins by Fourier-transform infrared spectroscopy. Phytochemistry 39:49-55 (1995).
- Rajadhyaksha M, Grossman M, Esterowitz D, Webb RH: *In vivo* confocal scanning laser microscopy of human skin: Melanin provides strong contrast. J Invest Dermatol 104:946-952 (1995).
- Romanenko LA, Mikhailov VV, Lysenko AM, Stepanenko VI: A new species of melanin-producing bacteria of the
- genus *Alteromonas*. Microbiology-Engl Tr 64:60-62 (1995). Schmitz S, Thomas PD, Allen TM, Poznansky MJ, Jimbow K: Dual role of melanins and melanin precursors as photoprotective and phototoxic agents: Inhibition of ultraviolet radiation-induced lipid peroxidation. Photochem Photobiol 61:650-655 (1995).
- Smit NPM, Westerhof W, Smit W, Nanninga B, Pavel S: Some aspects of melanin formation of melanocytes cultured on collagen-coated microcarrier beads. Pigm Cell Res 8:89-96 (1995).
- Soaresdasilva P: Nature and kinetic characteristics of L-DOPA uptake in rat renal proximal tubules. Amino Acids 8:265-270 (1995).
- Stano J, Nemec P, Weissova K, Kovacs P, Kakoniova D, Liskova D: Decarboxylation of L-tyrosine and L-dopa by immobilized cells of Papaver somniferum. Phytochemistry 38:859-860 (1995)
- Stromskaya TP, Filippova NA, Rybalkina EY, Egudina SV, Shtil AA, Éliseenkova AV, Stavrovskaya AA: Alterations of melanin synthesis in human melanoma cells selected in vitro for multidrug resistance. Exp Toxicol Pathol 47:157-166 (1995)
- Takahashi K, Suzuki H, Totsune K, Murakami O, Satoh F, Sone M, Sasano H, Mouri T, Shibahara S: Melaninconcentrating hormone in human and rat. Neuroendocrinology 61:493-498 (1995).
- Varela JM, Stempels NA, Vandenberghe DA, Tassignon MJ: Isoenzymic patterns of tyrosinase in the rabbit choroid and retina/retinal pigment epithelium. Exp Eye Res 60:621-629 (1995).
- Watanabe S, Saito T: Circular dichroism and ultraviolet studies of the cupric(II)-and nickel(II)-L-3,4dihydroxyphenylalanine complex. J Inorg Biochem 58:147-155 (1995).
- Wilczek A, Mishima Y: Inhibitory effects of melanin monomers, dihydroxyindole-2-carboxylic acid (DHICA) and dihydroxyindole (DHI) on mammalian tyrosinase, with a special reference to the role of DHICA/DHI ratio in melanogenesis. Pigm Cell Res 8:105-112 (1995).
 - Zareba M, Bober A, Korytowski W, Zecca L, Sarna T: The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Bba-Mol Basis Dis 1271:343-348 (1995).
 - Zhao SL, Thornquist SC, Barnstable CJ: *In vitro* transdifferentiation of embryonic rat retinal pigment epithelium to neural retina. Brain Res 677:300-310 (1995).

MELANOCYTES & KERATINOCYTES

- Abadir MC, Marghoob AA, Slade J, Salopek TG, Yadav S, Kopf AW: Case-control study of melanocytic nevi on the buttocks in atypical mole syndrome: Role of solar radiation in the pathogenesis of atypical moles. J Am Acad Dermatol 33:31-36 (1995).
- Aloi F, Solaroli C, Pippione M: Ínvolution of melanocytic nevi by halo eczema (Meyerson's nevi). European J Dermatology 5:313-315 (1995).
- Austin LM, Boissy RE: Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens: An avian model for human vitiligo. Am J Pathol 146:1529-1541 (1995).
- Bakker ABH, Schreurs MWJ, Tafazzul G, Deboer AJ, Kawakami Y, Adema GJ, Figdor CG: Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-Å2.1-restricted anti-melanoma CTL line. Int J Cancer 62:97-102 (1995).
- Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, Delpero JR, Birmbaum D, Hassoun J, Bonerandi JJ: Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 131:443-447 (1995).
- Cable J, Jackson IJ, Steel KP: Mutations at the W locus affect survival of neural crest-derived melanocytes in the mouse. Mech Develop 50:139-150 (1995).
- Carli P, Biggeri A, Giannotti B: Malignant melanoma in Italy: Risks associated with common and clinically atypical melanocytic nevi. J Am Acad Dermatol 32:734-739 (1995).
- Dupin E, Ledouarin NM: Retinoic acid promotes the differentiation of adrenergic cells and melanocytes in quail neural crest cultures. Dev Biol 168:529-548 (1995).
- Durham-Pierre DG, Walters CS, Halder RM, Pham HN, Vanderpool EA: Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 33:26-30 (1995).

- Hann SK, Im S, Pong HW, Park YK: Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol 32:943-948 (1995).
- Hou L, Kwon BS: Turtle lung cells produce a melanization-stimulating activity that promotes melanocytic differentiation of avian neural crest cells. Pigm Cell Res 8:113-119 (1995).
- Kageshita T, Yoshii A, Kimura T, Maruo K, Ono T, Himeno M, Nishimura Y: Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. Arch Dermatol Res 287:266-272 (1995).
- Kazianis S, Borowsky R: Stable association of a pigmentation allele with an oncogene: Nonhybrid melanomas in *Xiphophorus variatus*. J Hered 86:199-203 (1995).
- Krasagakis K, Garbe C, Eberle J, Orfanos CE: Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes *in vitro*. Arch Dermatol Res 287:259-265 (1995).
- Kubota R, Wang YM, Minoshima S, Kudoh J, Mashima Y, Oguchi Y, Shimizu N: Mapping of the human gene for a melanocyte protein Pmel 17 (D12S53E) to chromosome 12q13-q14. Genomics 26:430-431 (1995).
- Lecoin L, Lahav R, Martin FH, Teillet MA, Ledouarin NM: Steel and c-kit in the development of avian melanocytes: A study of normally pigmented birds and of the hyperpigmented mutant silky fowl. Develop Dynam 203:106-118 (1995).
- Masuda M, Yamazaki K, Kanzaki J, Hosoda Y: Ultrastructural evidence of cell communication between epithelial dark cells and melanocytes in vestibular organs of the human inner ear. Anat Rec 242:267-277 (1995).
- Masuda M, Yamazaki K, Matsunaga T, Kanzaki J, Hosoda Y: Melanocytes in the dark cell area of human vestibular organs. Acta Oto-Laryngol 152-157 (1995).
- Nataf V, Mercier P, Denechaud S, Guillemot JC, Capdevielle J, Lapointe F, Ledouarin NM: Melanoblast/melanocyte early marker (MelEM) is a glutathione S-transferase subunit. Exp Cell Res 218:394-400 (1995).
- Natali PG, Nicotra MR, Difilippo F, Bigotti A: Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. Br J Cancer 71:1243-1247 (1995).
- Nogales FF, Luna MA, Vergara E, Ovalle F, Lopezcantarero M: Small-cell epidermoid carcinoma with melanocyte colonization arising in a mature ovarian cystic teratoma. Arch Pathol Lab Med 119:551-554 (1995).
- Oconnor TJ: Mechanism of c-SRC activation in human melanocytes: Elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine. Cell Growth Differ 6:484(1995).
- Olsson MJ, Juhlin L: Transplantation of melanocytes in vitiligo. Br J Dermatol 132:587-591 (1995).
- Ortega VV, Diaz FM, Romero CC, Pacheco GO, Jordana MC, Rubiales FC: Abnormal melanosomes: Ultrastructural markers of melanocytic atypia. Ultrastruct Pathol 19:119-128 (1995).
- Peters TA, Kuijpers W, Tonnaer ELGM, Vanmuijen GNP, Jap PHK: Distribution and features of melanocytes during inner ear development in pigmented and albino rats. Hear Res 85:169-180 (1995).
- Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, Bowden GT: Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinogen 12:82-90 (1995).
- Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55:2713-2718 (1995).
- Reid K, Nishikawa SI, Bartlett PF, Murphy M: Steel factor directs melanocyte development *in vitro* through selective regulation of the number of c-kit(+) progenitors. Dev Biol 169:568-579 (1995).Rivers JK, Maclennan R, Kelly JW, Lewis AE, Tate BJ, Harrison S, Mccarthy WH: The Eastern Australian
- Rivers JK, Maclennan R, Kelly JW, Lewis AE, Tate BJ, Harrison S, Mccarthy WH: The Eastern Australian childhood nevus study: Prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. J Am Acad Dermatol 32:957-963 (1995).
- Schadendorf D, Kohlmus C, Gawlik Ć, Suter L, Czarnetzki BM: Mast cells in melanocytic tumours. Arch Dermatol Res 287:452-456 (1995).
- ⁹ Spritz RA, Hearing VJ: Genetic disorders of pigmentation. Advances in Human Genetics, 2 22:1-45 (1994).
- Sviderskaya EV, Wakeling WF, Bennett DC: A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes. Development 121:1547-1557 (1995).
- Swope VB, Medrano EE, Smalara D, Abdel-Malek ZA: Long-term proliferation of human melanocytes is supported by the physiologic mitogens α-melanotropin, endothelin- 1, and basic fibroblast growth factor. Exp Cell Res 217:453-459 (1995).

Tan JCS, Phang VPE: Inheritance of body pigmentation pattern in Brachydanio rerio. J Hered 86:231-232 (1995).

- Tronnier M, Kammerer R, Wolff HH: Proliferative activity of keratinocytes correlates with that of melanocytes in naevi and melanomas. Arch Dermatol Res 287:509-511 (1995).
- Tronnier M, Smolle J, Wolff HH: Ultraviolet irradiation induces acute changes in melanocytic nevi. J Invest Dermatol 104:475-478 (1995).
- Vijayasaradhi S, Houghton AN: Melanoma and melanocytes: Pigmentation, tumor progression, and the immune response to cancer. Advances in Pharmacology, Vol 32:343-374 (1995).
- Yamanishi DT, Meyskens FL: Alterations in gene expression and signal transductions in human melanocytes and melanoma cells. Crit Rev Oncogenesis 5:429-450 (1994).

----- 18 -----

- Zepter K, Haffner AC, Trefzer U, Elmets CA: Reduced growth factor requirements and accelerated cell- cycle kinetics in adult human melanocytes transformed with SV40 large T antigen. J Invest Dermatol 104:755-762 (1995)
- Zvulunov A, Esterly NB: Neurocutaneous syndromes associated with pigmentary skin lesions. J Am Acad Dermatol 32:915-935 (1995).

MELANOMA & METASTASIS

Akslen LA: Seasonal variation in melanoma progress. J Nat Cancer Inst 87:1025-1026 (1995).

- Alizadeh H, Ma D, Berman M, Bellingham D, Comerford SA, Gething MJH, Sambrook JF, Niederkorn JY: Tissuetype plasminogen activator-induced invasion and metastasis of murine melanomas. Curr Eye Res 14:449-458 (1995).
- Atzpodien J, Hanninen EL, Kirchner H, Franzke A, Korfer AK, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H: Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon- α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31A:876-881 (1995).
- Autier P, Dore JF, Schifflers E, Cesarini JP, Bollaerts A, Koelmel KF, Gefeller O, Liabeuf A, Lejeune F, Lienard D, Joarlette M, Chemaly P, Kleeberg UR: Melanoma and use of sunscreens: An EORTC case-control study in Germany, Belgium and France. Int J Cancer 61:749-755 (1995).
- Auzenne E, Feig B, Ross MI, Tomasovic SP, Klostergaard J: Tetramodality treatment of human melanoma in vitro. Melanoma Res 5:49-57 (1995).
- Baba H, Urano T, Okada K, Furukawa K, Nakayama E, Tanaka H, Iwasaki K, Shiku H: Two isotypes of murine nm23/nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in metastatic suppression of a murine melanoma line. Cancer Res 55:1977-1981 (1995)
- Bauer M, Reaman GH, Hank JA, Cairo MS, Anderson P, Blazar BR, Frierdich S, Sondel PM: A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma: Á childrens cancer group study. Cancer 75:2959-2965 (1995).
- Belkhou R, Abbe JC, Pham P, Jasner N, Sahel J, Dreyfus H, Moutaouakkil M, Massarelli R: Uptake and metabolism of boronophenylalanine in human uveal melanoma cells in culture Relevance to boron neutron capture therapy of cancer cells. Amino Acids 8:217-229 (1995).
- Berwick M, Chen YT: Reliability of reported sunburn history in a case-control study of cutaneous malignant melanoma. Am J Epidemiol 141:1033-1037 (1995). Beviglia L, Stewart GJ, Niewiarowski S: Effect of four disintegrins on the adhesive and metastatic properties of
- BI6F10 melanoma cells in a murine model. Oncol Res 7:7-20 (1995).
- Bitan M, Mohsen M, Levi E, Wygoda MR, Miao HQ, Lider O, Svahn CM, Ekre HP, Ishaimichaeli R, Barshavit R, Vlodavsky I, Peretz T: Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin. Isr J Med Sci 31:106-118 (1995).
- Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M, Stevens MFG: Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913 (1995).
- Boni R, Boni RAH, Steinert H, Burg G, Buck A, Marincek B, Berthold T, Dummer R, Voellmy D, Ballmer B, Vonschulthess GK: Staging of metastatic melanoma by whole-body positron emission tomography using 2fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 132:556-562 (1995).
- Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, Maio M: Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer 61:548-556 (1995).
- Brent PJ, Pang GT: sigma Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 278:151-160 (1995).
- Buttner P, Garbe C, Bertz J, Burg G, Dhoedt B, Drepper H, Guggenmoosholzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 75:2499-2506 (1995)
- Castella AP, Bercher L, Zografos L, Egger E, Herbort CP: Study of the blood-aqueous barrier in choroidal melanoma. Br J Ophthalmol 79:354-357 (1995).
- Cilenti L, Toniato E, Ruggiero P, Fusco C, Farina AR, Tiberio A, Hayday AC, Gulino A, Frati L, Martinotti S: Transcriptional modulation of the human intercellular adhesion molecule gene I (ICAM-1) by retinoic acid in melanoma cells. Exp Cell Res 218:263-270 (1995).
- Ciotti P, Rainero ML, Nicolo G, Spina B, Garre C, Casabona F, Santi PL, Bianchi-Scarra G: Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res 5:41-47 (1995).
- Clauser KR, Hall SC, Smith DM, Webb JW, Andrews LE, Tran HM, Epstein LB, Burlingame AL: Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc Natl Acad Sci USA 92:5072-5076 (1995).

----- 19 -----

- Coates AS, Ingvar CI, Petersenschaefer K, Shaw HM, Milton GW, Obrien CJ, Thompson JF, Mccarthy WH: Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney melanoma unit from 1960 to 1991. J Amer Coll Surgeons 180:402-409 (1995).
- Danen EHJ, Jansen KFJ, Vankraats AA, Cornelissen IMHA, Ruiter DJ, Vanmuijen GNP: $\alpha(v)$ -integrins in human melanoma: Gain of $\alpha(v)\beta(3)$ and loss of $\alpha(v)\beta(5)$ are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int J Cancer 61:491-496 (1995).
- Danen EHJ, Vanmuijen GNP, Ruiter DJ: Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv 24:43-65 (1995).
- Deberker D: Aid to diagnosis of melanoma in primary medical care Doubling of excisions of genuine disease is the important issue. Br Med J 310:1328(1995)
- Dehner LP, Wick MR: S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: A totally dedifferentiated malignant melanoma? Reply. Am J Clin Pathol 103:773(1995).
- Delmar CB, Green AC: Aid to diagnosis of melanoma in primary medical care Doubling of excisions of genuine disease is the important issue Reply. Br Med J 310:1328(1995).
- Dereure O, Guillot B, Laurent E, Arnaud B, Guilhou JJ: Ocular malignant melanoma in a patient with van Recklinghausen's disease. European J Dermatology 5:117-121 (1995).
- Derooij MJM, Rampen FHJ, Schouten LJ, Neumann HAM: Skin cancer screening focusing on melanoma yields more selective attendance. Arch Dermatol 131:422-425 (1995).
- Donin N, Sinai J, Michowitz M, Hiss J, Nordenberg J, Leibovici J: Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Mech Ageing Dev 80:121-137 (1995)
- Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB: Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67-68 (1995).
- Eberle J, Garbe C, Orfanos CE: Identification of genes specifically regulated in human melanoma cells. Arch Dermatol Res 287:421-427 (1995).
- Evans RA: Elective lymph node dissection for malignant melanoma: The tumor burden of nodal disease. Anticancer Res 15:575-579 (1995)
- Favaro D, Santarosa M, Quaia M, Spada A, Freschi A, Talmini R, Galligioni E: Soluble intercellular adhesion molecule-1 in melanoma patients treated with liposomes containing muramyl tripeptide. Eur J Cancer 31A:1026-1027 (1995)
- Fierlbeck G, Schreiner T, Rassner G: Combination of highly purified human leukocyte interferon α and 13-cisretinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother 40:157-164 (1995).
- Foppoli M, Citterio G, Polastri D, Guerrieri R: The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous α -interferon with polychemotherapy in advanced malignant melanoma. Tumori 81:102-106 (1995).
- Foss AJE, Guille MJ, Occleston NL, Hykin PG, Hungerford JL, Lightman S: The detection of melanoma cells in peripheral blood by reverse transcription polymerase chain reaction. Br J Cancer 72:155-159 (1995).
- Frohlich E, Schaumburglever G, Klessen C: Immunocytochemical and immunoelectron microscopic
- demonstration of cathepsin B in human malignant melanoma. Br J Dermatol 132:867-875 (1995).
 Garbe C, Buttner P, Bertz J, Burg G, Dhoedt B, Drepper H, Guggenmoosholzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75:2484-2491 (1995).
- Garbe C, Buttner P, Bertz J, Burg G, Dhoedt B, Drepper H, Guggenmoosholzmann I, Lechner W, Lippold A, Orfanos CE, Peters A, Rassner G, Stadler R, Stroebel W: Primary cutaneous melanoma: Prognostic classification of anatomic location. Cancer 75:2492-2498 (1995).
- Gelsleichter L, Gown AM, Zarbo RJ, Wang E, Coltrera MD: p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Modern Pathol 8:530-535 (1995).
- Gold JE, Ross SD, Krellenstein DJ, Larosa F, Malamud SC, Osband ME: Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients. Eur J Cancer 31A:698-708 (1995)
- Gold JE, Zachary DT, Osband ME: Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor- specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Int J Cancer 61:580-586 (1995).
- Grossniklaus HE, Barron BC, Wilson MW: Murine model of anterior and posterior ocular melanoma. Curr Eye Res 14:399-404 (1995)
- Gruis NA, Vandervelden PA, Sandkuijl LA, Prins DE, Weaverfeldhaus J, Kamb A, Bergman W, Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-353 (1995).
- Gruis NA, Weaverfeldhaus J, Liu QY, Frye C, Eeles R, Orlow I, Lacombe L, Poncecastaneda V, Lianes P, Latres E, Skolnick M, Cordoncardo C, Kamb A: Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146:1199-1206 (1995).
- Guo HB, Stoffelwagner B, Bierwirth T, Mezger J, Klingmuller D: Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer 31A:924-928 (1995).
 Gutman M, Singh RK, Xie KP, Bucana CD, Fidler IJ: Regulation of interleukin-8 expression in human melanoma
- cells by the organ environment. Cancer Res 55:2470-2475 (1995).

- Hahkakemppinen M, Muhonen T, Virolainen M, Jekunen A, Askoseljavaara S, Pyrhonen S: Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol 132:973-977 (1995).
- Hamby CV, Mendola CE, Potla L, Stafford G, Backer JM: Differential expression and mutation of NME genes in autologous cultured human melanoma cells with different metastatic potentials. Biochem Biophys Res Commun 211:578-585 (1995).
- Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN: Rejection of mouse melanoma elicited by local secretion of interleukin-2: Implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 61:253-260 (1995)
- Harrison DA, Hodge DO, Bourne WM: Óutcome of corneal grafting with donor tissue from eyes with primary choroidal melanomas: A retrospective cohort comparison. Arch Ophthalmol 113:753-756 (1995).
- Hedblad MA, Borglund E: Precursor lesion of malignant melanoma in xeroderma pigmentosum: Reflections about solar lentigo as the precursor. J Am Acad Dermatol 32:680-681 (1995).
- Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Yao TJ, Oettgen HF, Livingston PO: G(M2)-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788 (1995).
- Herbst RA, Larson A, Weiss J, Cavenee WK, Hampton GM, Arden KC: A defined region of loss of heterozygosity at 11q23 in cutaneons malignant melanoma. Cancer Res 55:2494-2496 (1995).
- Herd RM, Cooper EJ, Hunter JAA, Mclaren K, Chetty U, Watson ACH, Gollock J: Cutaneous malignant melanoma. Publicity, screening clinics and survival The Edinburgh experience 1982-90. Br J Dermatol 132:563-570 (1995).
- Herlyn D, Somasundaram R, Zaloudik J, Li W, Jacob L, Harris D, Kieny MP, Ricciardi R, Gonczol E, Sears H, Mastrangelo M: Cloned antigens and antiidiotypes. Hybridoma 14:159-166 (1995). Heymann D, Blanchard F, Raher S, Degroote D, Godard A: Modulation of LIF expression in human melanoma
- cells by Oncostatin M. Immunol Lett 46:245-251 (1995).
- Hiraga T, Nakajima T, Ozawa H: Bone resorption induced by a metastatic human melanoma cell line. Bone 16:349-356 (1995).
- Hodge WG, Duclos AJ, Rocha G, Antecka E, Baines MG, Corriveau C, Brownstein S, Deschenes J: DNA index and S phase fraction in uveal malignant melanomas. Br J Ophthalmol 79:521-526 (1995).
- Holly EA, Aston DA, Cress RD, Ähn DK, Kristiansen JJ: Cutaneous melanoma in women. 1. Exposure to sunlight, ability to tan, and other risk factors related to ultraviolet light. Am J Epidemiol 141:923-933 (1995).
- Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ: Cutaneous melanoma in women. 2. Phenotypic characteristics and other host-related factors. Am J Epidemiol 141:934-942 (1995).
- Holly EA, Cress RD, Ahn DK: Cutaneous melanoma in women. 3. Reproductive factors and oral contraceptive use. Am J Epidemiol 141:943-950 (1995).
- Iida J, Meijne AML, Spiro RC, Roos E, Furcht LT, Mccarthy JB: Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma- associated proteoglycan (NG2) and α 4 β 1 integrin. Cancer Res 55:2177-2185 (1995). Inokuchi J, Usuki S, Jimbo M: Stimulation of glycosphingolipid biosynthesis by L-threo-1-phenyl-2-
- decanoylamino-1-propanol and its homologs in B16 melanoma cells. J Biochem Tokyo 117:766-773 (1995).
- Inoue S, Hasegawa K, Ito S, Ozeki H, Solano F, Jimenez-Cervantes C, Wakamatsu K, Fujita K: Antimelanoma effect of 4-S-cysteaminylcatechol, an activated form of 4-S-cysteaminylphenol. Cancer Res 55:2603-2607 (1995). Iscovich J, Ackerman C, Andreev H, Peer J, Steinitz R: An epidemiological study of posterior uveal melanoma in Israel, 1961-1989. Int J Cancer 61:291-295 (1995).
- Jiang HP, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB: The melanoma differentiationassociated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10:1855-1864 (1995).
- Johnson TM, Smith JW, Nelson BR, Chang A: Current therapy for cutaneous melanoma. J Am Acad Dermatol 32:689-707 (1995)
- Joob AW, Haines GK, Kies MS, Shields TW: Primary malignant melanoma of the esophagus. Ann Thorac Surg 60:217-222 (1995).
- Kageshita T, Hirai S, Kimura T, Hanai N, Ohta S, Ono T: Association between sialyl Lewis(a) expression and tumor progression in melanoma. Cancer Res 55:1748-1751 (1995).
- Karakousis CP, Driscoll DL: Prognostic parameters in localised melanoma: Gender versus anatomical location. Eur J Cancer 31A:320-324 (1995).
- Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang XQ, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968 (1995).

Keeley D: Screening for melanoma risk is misguided. Br Med J 310:916(1995).

- Kleeberg UR, Eggermont AM: Twenty-five years of pluridisciplinary approach for melanoma patients. The European Organization on Research and Treatment of Cancer Melanoma Cooperative Group (EORTC-MCG). Melanoma Res 5:69-72 (1995).
- Koop S, Macdonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC: Fate of melanoma cells entering the microcirculation: Over 80% survive and extravasate. Cancer Res 55:2520-2523 (1995).

Krag DN, Meijer SJ, Weaver DL, Loggie BW, Harlow SP, Tanabe KK, Laughlin EH, Alex JC: Minimal-access surgery for staging of malignant melanoma. Arch Surg 130:654-658 (1995).

Krauss JC, Cameron MJ, Park AN, Forslund K, Chang AE: Efficient transduction of early passage human melanoma to secrete IL-4. J Immunol Methods 183:239-250 (1995).

- Kruit WHJ, Goey SH, Calabresi F, Lindemann A, Stahel RA, Poliwoda H, Osterwalder B, Stoter G: Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma. Br J Cancer 71:1319-1321 (1995).
- Lasek W, Wankowicz A, Kuc K, Feleszko W, Golab J, Giermasz A, Wiktorjedrzejczak W, Jakobisiak M: Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colonystimulating factor in a MmB16 melanoma model in mice. Cancer Immunol Immunother 40:315-321 (1995).
- Laskin WB, Knittel DR, Frame JN: S100 protein and HMB-45 negative "rhabdoid" malignant melanoma: A totally dedifferentiated malignant melanoma? Am J Clin Pathol 103:772-773 (1995).
- Lee KY, Goedegebuure PS, Linehan DC, Eberlein TJ: Immunoregulatory effects of CD4(+) T helper subsets in human melanoma. Surgery 117:365-372 (1995).
- Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340-347 (1995).
- Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM: Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma: The influence of additional therapy after total skin electron beam radiation. Arch Dermatol 131:432-435 (1995).
- Little P, Keefe M, White J: Self screening for risk of melanoma: Validity of self mole counting by patients in a single general practice. Br Med J 310:912-916 (1995).
- Logani S, Cho AS, Su LD, Withers HR, Mcbride WH, Hall MO, Lee DA, Milani JK, Straatsma BR: Effects of γ radiation on the OM431 human ocular melanoma cell line. Exp Eye Res 60:603-605 (1995).
- Longatto A, Decarvalho LV, Santos GD, Oyafuso MS, Lombardo V, Bortolan J, Neves JI: Cytologic diagnosis of melanoma in serous effusions A morphologic and immunocytochemical study. Acta Cytol 39:481-484 (1995).
- Luyten GPM, Mooy CM, Eijkenboom WMH, Stijnen T, Hellemons LP, Luider TM, Dejong PTVM: No demonstrated effect of pre-enucleation irradiation on survival of patients with uveal melanoma. Am J Ophthalmol 119:786-791 (1995).
- Maass G, Schweighoffer T, Berger M, Schmidt W, Herbst E, Zatloukal K, Buschle M: Tumor vaccines: Effects and fate of IL-2 transfected murine melanoma cells *in vivo*. Int J Immunopharmacol 17:65(1995).
- Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J, Wiznerowicz M, Hawley RG, Heinrich PC, Rosejohn S: Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 6:805-811 (1995).
- Macneill IB, Elwood JM, Miller D, Mao Y: Trends in mortality from melanoma in Canada and prediction of future rates. Stat Med 14:821-839 (1995).
- Marchetti D, Mccutcheon IE, Ross MJ, Nicolson GL: Inverse expression of neurotrophins and neurotrophin receptors at the invasion front of human melanoma brain metastases. Int J Oncol 7:87-94 (1995).
- Marghoob AA, Slade J, Kopf AW, Rigel DS, Friedman RJ: The ABCDs of melanoma: Why change? J Am Acad Dermatol 32:682-684 (1995).
- Mastrangelo MJ: Current clinical practice: Cutaneous melanoma: How much surgery is enough? Response. Semin Oncol 22:R16(1995).
- Masuda T, Watanabe S, Amemiya M, Ishizuka M, Takeuchi T: Inhibitory effect of cytostatin on spontaneous lung metastases of B16-BL6 melanoma cells. J Antibiot 48:528-529 (1995).
- Melia J: Early detection of cutaneous malignant melanoma in Britain. Int J Epidemiol 24:S39-S44 (1995).
- Melia J, Frost T, Grahambrown R, Hunter J, Marsden A, Duvivier G, Warin AP, White J, Whitehead S, Wroughton M, Ellman R, Chamberlain J: Problems with registration of cutaneous malignant melanoma in England. Br J Cancer 72:224-228 (1995).
- Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB: A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer 75:2251-2257 (1995).
- Mittelman A, Wang XH, Matsumoto K, Ferrone S: Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14:175-181 (1995).
 - Morioka N, Kikumoto Y, Hoon DSB, Morton DL, Irie RF: Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 32:573-581 (1995).
 - Moynihan GD: The ABCDs of melanoma: Why change? Reply. J Am Acad Dermatol 32:684(1995).
 - Naldi L, Locati F, Finazzi G, Barbui T, Cainelli T: Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 75:2784-2785 (1995).
 - Nip J, Rabbani SA, Shibata HR, Brodt P: Coordinated expression of the vitronectin receptor and the urokinasetype plasminogen activator receptor in metastatic melanoma cells. J Clin Invest 95:2096-2103 (1995).
 - O'Connor TJ, Fujita DJ: Differentiation of B16 murine melanoma cells is associated with an increased level of c-SRC. Melanoma Res 5:5-13 (1995).
 - Olney RC, Anhalt H, Neely EK, Wilson DM: A quantitative assay for IGF-I and IGF binding protein mRNAs: Expression in malignant melanoma cells. Mol Cell Endocrinol 110:213-223 (1995).

----- 22 -----

- Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G: A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand J Immunol 41:357-364 (1995).
- Oosterhuis JA, Journeedekorver HG, Kakebeekekemme HM: Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 113:693(1995).
- Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, Mckenzie RC: Expression of leukemia inhibitory factor and interleukin- 11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. J Interferon Cytokine
- Res 15:455-460 (1995). Palomares T, Bilbao P, Alonsovarona A, Barberaguillem E: The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma. Cancer Immunol Immunother 40:292-298 (1995).

Pearce RL: Subungual desmoplastic melanoma in an aboriginal woman. Med J Aust 162:611-612 (1995).

- Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R: Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet 80:40-46 (1995).
- Prezioso JA, Hearing VJ, Muller J, Urabe K, Wang N, Gorelik E: Impairment of the melanogenic pathway in B16 melanoma cells transfected with class 1 H-2 genes. Melanoma Res 5:15-26 (1995).
- Punt CJA, Tytgat JH, Vanliessum PA, Gerard B: Fotemustine and tamoxifen combination therapy in metastatic malignant melanoma. A phase II study. Eur J Cancer 31A:421-422 (1995).
- Rampen FHJ, Casparievanvelsen IJAMG, Vanhuystee BEWL, Kiemeney LALM, Schouten LJ: False-negative findings in skin cancer and melanoma screening. J Am Acad Dermatol 33:59-63 (1995)
- Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC: Mutations associated with familial melanoma impair p16(INK4) function. Nat Genet 10:114-116 (1995).
- Rennie I: Uveal melanoma: Cell cycles and survival. Br J Ophthalmol 79:513-514 (1995).
- Richmond I, Eyden BP, Banerjee SS: Intranodal Langerhans' cell histiocytosis associated with malignant melanoma. Histopathology 26:380-382 (1995)
- Robbins PF, Elgamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumorinfiltrating lymphocytes. J Immunol 154:5944-5950 (1995).
- Rosenblum MG, Cheung L, Mujoo K, Murray JL: An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: Tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol Immunother 40:322-328 (1995).
- Rummelt V, Folberg R, Woolson RF, Hwang T, Peer J: Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology 102:844-851 (1995).
- Sagebiel RW: Who needs zebras? Comments on desmoplastic melanoma. J Am Acad Dermatol 32:800-802 (1995).
- Sarkar S, Flores I, Ron Y, Derosa C, Ozzello L, Pestka S: Injection of irradiated B16 melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int J Oncol 7:17-24 (1995).
- Schadendorf D, Herfordt R, Czarnetzki BM: P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 132:551-555 (1995).
- Schultz N, Oratz R, Chen DL, Zeleniuchjacquotte A, Abeles G, Bystryn JC: Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 13:503-508 (1995).
- Schwechheimer K, Zhou LP: HMB45: A specific marker for melanoma metastases in the central nervous system? Virchows Archiv 426:351-353 (1995).
- Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T, Brichard V, Boon T, Bordignon C, Anichini A, Parmiani G: Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 92:5674-5678 (1995).
- Shrayer D, Bogaars H, Hearing VJ, Maizel A, Wanebo H: Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine. Cancer Immunol Immunother 40:277-282 (1995).
 - Shumate CR, Urist MM, Maddox WA: Melanoma recurrence surveillance: Patient or physician based? Ann Surg 221:566-571 (1995)
 - Silvani A, Ferrari G, Paonessa G, Toniatti C, Parmiani G, Colombo MP: Down-regulation of interleukin 6 receptor α chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M. Cancer Res 55:2200-2205 (1995)
 - Sivam GP, Martin PJ, Reisfeld RA, Mueller BM: Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 55:2352-2356 (1995).
 - Skelton HG, Smith KJ, Laskin WB, Mccarthy WF, Gagnier JM, Graham JH, Lupton GP: Desmoplastic malignant melanoma. J Am Acad Dermatol 32:717-725 (1995).
 - Spruss T, Bernhardt G, Schonenberger H, Schiess W: Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol 121:193-202 (1995). Stanganelli I, Raccagni AA, Baldassari L, Calista D, Serafini M, Bucchi L: Analysis of Breslow tumor thickness
 - distribution of skin melanoma in the Italian region of Romagna, 1986-1991. Tumori 80:416-421 (1994).
 - Steinert HC, Boni RAH, Buck A, Boni R, Berthold T, Marincek B, Burg G, Vonschulthess GK: Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 195:705-709 (1995).
 - Stern JB: Precursor lesion of malignant melanoma in xeroderma pigmentosum: Reflections about solar lentigo as the precursor - Reply. J Am Acad Dermatol 32:681-682 (1995).

Swerdlow AJ, English JSC, Qiao Z: The risk of melanoma in patients with congenital nevi: A cohort study. J Am Acad Dermatol 32:595-599 (1995).

- Swerdlow AJ, Storm HH, Sasieni PD: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 61:773-779 (1995).
- Finar J, Bazaz R, Kimler V, Haddad M, Tang DG, Robertson D, Tovari J, Taylor JD, Honn KV: Immunomorphological characterization and effects of 12-(S)- HETE on a dynamic intracellular pool of the α(IIb)β(3)-integrin in melanoma cells. J Cell Sci 108:2175-2186 (1995).
- Travers RL, Sober AJ, Berwick M, Mihm MC, Barnhill RL, Duncan LM: Increased thickness of pregnancyassociated melanoma. Br J Dermatol 132:876-883 (1995).

Tufto I, Rofstad EK: Transient perfusion in human melanoma xenografts. Br J Cancer 71:789-793 (1995).

- Tufto I, Rofstad EK: Interstitial fluid pressure in human melanoma xenografts -Relationship to fractional tumor water content, tumor size, and tumor volume-doubling time. Acta Oncol 34:361-365 (1995).
- Tyler DS, Francis GM, Frederick M, Tran AH, Ordonez NG, Smith JL, Eton O, Ross M, Grimm EA: Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res 15:331-340 (1995).
- Vandenbrule FA, Buicu C, Baldet M, Sobel ME, Cooper DNW, Marschal P, Castronovo V: Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 209:760-767 (1995).
- Vanmuijen GNP, Danen EHJ, Veerkamp JH, Ruiter DJ, Lesley J, Vandenheuvel LPWJ: Glycoconjugate profile and CD44 expression in human melanoma cell lines with different metastatic capacity. Int J Cancer 61:241-248 (1995).
- Veiga SS, Chammas R, Cella N, Brentani RR: Glycosylation of β-1 integrins in B16-F10 mouse melanoma cells as determinant of differential binding and acquisition of biological activity. Int J Cancer 61:420-424 (1995).
- Verhaegh MEJM, Sanders CJG, Arends JW, Neumann HAM: Expression of the apoptosis-suppressing protein Bcl-2 in non-melanoma skin cancer. Br J Dermatol 132:740-744 (1995).
- Verschraegen CF, Mendoza JT, Kozielski AJ, Giovanella BC: Modulation of the response to chemotherapy in a human melanoma clone by the site of growth in the nude mouse. Anticancer Res 15:9-11 (1995).
- Vuoristo MS, Grohn P, Kellokumpulehtinen P, Turunen M, Joensuu H, Kumpulainen E, Korpela M, Tiusanen K, Nevantaus A: Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 121:175-180 (1995).
- Wagner SN, Ockenfels HM, Wagner C, Hofler H, Goos M: Ras gene mutations: A rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol 104:868-871 (1995).
- Wakeling WF, Souberbielle BE, Bennett DC: Detection of a human DNA sequence correlated with melanocyte-like differentiation and tumour suppression after transfection into murine melanoma cells. Melanoma Res 5:27-40 (1995).
- Walsh P, Dorner A, Duke RC, Su LJ, Glode LM: Macrophage colony-stimulating factor complementary DNA: A candidate for gene therapy in metastatic melanoma. J Nat Cancer Inst 87:809-816 (1995).
- Wellbrock C, Lammers R, Ullrich A, Schartl M: Association between the melanoma-inducing receptor tyrosine kinase Xmrk and src family tyrosine kinases in Xiphophorus. Oncogene 10:2135-2143 (1995).
- Westerdahl J, Olsson H, Masback A, Ingvar C, Jonsson N: Is the use of sunscreens a risk factor for malignant melanoma? Melanoma Res 5:59-65 (1995).
- White TK, Zhu QA, Tanzer ML: Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem 270:15926-15929 (1995).
- Yamasaki S, Okino T, Chakraborty NG, Adkisson WO, Sampieri A, Padula SJ, Mauri F, Mukherji B: Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother 40:268-271 (1995).
- Zolzer F, Streffer C: Cell cycle-dependent expression of Ki-67 antigen in human melanoma cells subjected to irradiation and/or hyperthermia. Radiat Res 143:98-101 (1995).

MSH, POMC, GROWTH FACTORS & RECEPTORS

- Bagutti C, Oestreicher M, Siegrist W, Oberholzer M, Eberle AN: α-MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. J Recept Signal Transduct Res 15:427-442 (1995).
- Balm PHM, Hovens MLM, Bonga SEW: Endorphin and MSH in concert form the corticotropic principle released by tilapia (*Oreochromis mossambicus*, Teleostei) melanotropes. Peptides 16:463-469 (1995).
- Brett PM, Curtis D, Robertson MM, Gurling HMD: The genetic susceptibility to Gilles de la Tourette Syndrome in a large multiple affected British kindred: Linkage analysis excludes a role for the genes coding for dopamine D1, D2, D3, D4, D5 receptors, dopamine β hydroxylase, tyrosinase, and tyrosine hydroxylase. Biol Psychiatry 37:533-540 (1995).
- Carrel S, Hartmann F, Salvi S, Albrecht H, Schreyer M, Rimoldi D: Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN γ. Int J Cancer 62:76-83 (1995).
- Chin Y, Janssens J, Bleus J, Vandevijver C, Zhang JW, Raus J: T cell receptor V β usage of tumor infiltrating lymphocyte lines cloned from human breast tumor and melanoma. Int J Oncol 7:147-153 (1995).
- Chlubadetapia J, Bagutti C, Wikberg JS, Chhajlani V, Eberle AN: Stable expression of the human MSH receptor in a mouse melanoma cell line. J Recept Signal Transduct Res 15:43-53 (1995).

- Cohen T, Gitaygoren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G: VEGF(121), a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell- surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270:11322-11326 (1995).
 - Coleman A, Robertson G, Lugo TG: Growth control by tumor suppressors in malignant melanoma. Receptor 5:9-19 (1995).
 - Davol P, Beitz JG, Frackelton AR: Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. J Invest Dermatol 104:916-921 (1995).
- Dean AD, Frost-Mason SK: Effects of melanocyte-stimulating hormone on wild-type and white axolotl neural crest cells. Biochem Biophys Res Commun 210:239-245 (1995).
- Dewildt DJ, Kasbergen CM, Versteeg DHG: Effect of γ(2)-melanocyte-stimulating hormone on cerebral blood flow in rats. J Cardiovasc Pharmacol 25:898-905 (1995).
- Drozdz R, Eberle AN: Binding sites for melanin-concentrating: Hormone (MCH) in brain synaptosomes and membranes from peripheral tissues identified with highly tritiated MCH. J Recept Signal Transduct Res 15:487-502 (1995)
- Dyer JK, Philipsen HLA, Tonnaer JADM, Hermkens PHH, Haynes LW: Melanocortin analogue Org2766 binds to rat Schwann cells, upregulates NGF low-affinity receptor p75, and releases neurotrophic activity. Peptides 16:515-522 (1995).
- Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC: Protein B61 as a new growth factor: Expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 55:2528-2532 (1995).
 - Facchinetti F, Bernasconi S, Iughetti L, Genazzani AD, Ghizzoni L, Genazzani AR: Changes in dopaminergic control of circulating melanocyte-stimulating hormone-related peptides at puberty. Pediatr Res 38:91-94 (1995)
 - Fischer ÉG, Ruf W, Mueller BM: Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 55:1629-1632 (1995).
 - Francis K, Baker BI: Developmental changes in melanin-concentrating hormone in Rana temporaria. Gen Comp Endocrinol 98:157-165 (1995).
 - Garratt PJ, Jones R, Tocher DA, Sugden D: Mapping the melatonin receptor .3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. J Med Chem 38:1132-1139 (1995).
 - Griffond B, Deray A, Nguyen NU, Colard C, Fellmann D: The synthesis of melanin-concentrating hormone is stimulated by ventromedial hypothalamic lesions in the rat lateral hypothalamus: A time-course study. Neuropeptides 28:267-275 (1995).
 - Groneveld D, Eckhardt ERM, Coenen AJM, Martens GJM, Balm PHM, Bonga SEW: Expression of tilapia prepro-melanin-concentrating hormone mRNA in hypothalamic and neurohypophysial cells. J Molecular Endocrinol 14:199-207 (1995)
- Haskellluevano C, Shenderovich MD, Sharma SD, Nikiforovich GV, Hadley ME, Hruby VJ: Design, synthesis, biology, and conformations of bicyclic α -melanotropin analogues. J Med Chem 38:1736-1750 (1995).
 - Hervieu G, Nahon JL: Pro-melanin concentrating hormone messenger ribonucleic acid and peptides expression in peripheral tissues of the rat. Neuroendocrinology 61:348-364 (1995). Hesselgesser J, Chitnis CE, Miller LH, Yansura DG, Simmons LC, Fairbrother WJ, Kotts C, Wirth C, Gillececastro
 - BL, Horuk R: A mutant of melanoma growth stimulating activity does not activate neutrophils but blocks erythrocyte invasion by malaria. J Biol Chem 270:11472-11476 (1995).
- Hill HZ, Hill GJ, Cieszka K, Azure M, Chowdhary I, Sayre RM: A multitherapy resistance factor from melanoma reveals that killing by near UV is different from genotoxic agents. Photochem Photobiol 61:479-483 (1995).
 - Kawai S, Yahata N, Nishida S, Nagai K, Mizushima Y: Dehydroepiandrosterone inhibits B16 mouse melanoma cell growth by induction of differentiation. Anticancer Res 15:427-431 (1995).
 - Kim Y, Carpenter AM, Gregg KJ, Shahnaz Z, Carr JA: Diurnal variation in α-melanocyte-stimulating hormone content of various brain regions and plasma of the Texas toad, Bufo speciosus. Gen Comp Endocrinol 98:50-56 (1995)
 - Kosano H, Setogawa T, Kobayashi K, Nishigori H: Pyrroloquinoline quinone (PQQ) inhibits the expression of tyrosinase mRNA by α-melanocyte stimulating hormone in murine B16 melanoma cells. Life Sci 56:1707-1713 (1995)
 - Lamacz M, Garnier M, Hery F, Tonon MC, Vaudry H: Adrenergic control of α -melanocyte-stimulating hormone release in frog pituitary is mediated by both β and a nonconventional $\alpha(2)$ -subtype of adrenoreceptors. Neuroendocrinology 61:430-436 (1995).
 - Lincoln GA, Baker BI: Seasonal and photoperiod-induced changes in the secretion of α -melanocyte-stimulating hormone in Soay sheep: Temporal relationships with changes in β -endorphin, prolactin, follicle-stimulating hormone, activity of the gonads and growth of wool and horns. J Endocrinol 144:471-481 (1995).
 - Miwa H, Gantz I, Konda Y, Shimoto Y, Yamada T: Structural determinants of the melanocortin peptides required
 - for activation of melanocortin-3 and melanocortin-4 receptors. J Pharmacol Exp Ther 273:367-372 (1995). Nozaki M, Takahashi A, Amemiya Y, Kawauchi H, Sower SA: Distribution of lamprey adrenocorticotropin and melanotropins in the pituitary of the adult sea lamprey, Petromyzon marinus. Gen Comp Endocrinol 98:147-156 (1995)
 - Prusis P, Frandberg PA, Muceniece R, Kalvinsh I, Wikberg JES: A three dimensional model for the interaction of MSH with the melanocortin-1 receptor. Biochem Biophys Res Commun 210:205-210 (1995).

- Rogivue C, Car BD, Allmanniselin I, Zwahlen RD, Walz A: Bovine melanoma growth stimulatory activity: A new monocyte-macrophage derived cytokine of the IL-8 family Partial structure, function, and expression in acute pulmonary inflammation. Lab Invest 72:689-695 (1995).
- Shimizu H, Tanaka Y, Sato N, Mori M: α-Melanocyte-stimulating hormone (MSH) inhibits insulin secretion in HIT-T 15 cells. Peptides 16:605-608 (1995).
- Siegrist W, Eberle AN: Melanocortins`and´their implication in melanoma. Trends Endocrinol Metab 6:115-120 (1995).
- Siegrist Ŵ, Sauter P, Eberle AN: A selective protein kinase C inhibitor (CGP 41251) positively and negatively modulates melanoma cell MSH receptors. J Recept Signal Transduct Res 15:283-296 (1995).
- Vanstrien FJC, Galas L, Jenks BG, Roubos EW: Differential acetylation of pro-opiomelanocortin-derived peptides in the pituitary gland of *Xenopus laevis* in relation to background adaptation. J Endocrinol 146:159-167 (1995).

TYROSINASE, TYROSINASE RELATED PROTEINS & MOLECULAR BIOLOGY

- Bassi MT, Schiaffino MV, Renieri A, Denigris F, Galli L, Bruttini M, Gebbia M, Bergen AAB, Lewis RA, Ballabio A: Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. Nat Genet 10:13-19 (1995).
- Brey PT, Ahmed A, Lee WJ, Ashida M, Lehane MJ: Tyrosinase-type prophenoloxidase distribution in the alimentary canal of strains of *Anopheles gambiae* refractory and susceptible to Plasmodium infection. Exp Parasitol 80:654-664 (1995).
- Cooksey CJ, Land EJ, Ramsden CA, Riley PA: Tyrosinase-mediated cytotoxicity of 4-substituted phenols: Quantitative structure-thiol-reactivity relationships of the derived o-quinones. Anti-Cancer Drug Des 10:119-129 (1995).
- Deng Q, Dong SJ: Construction of a tyrosinase-based biosensor in pure organic phase. Anal Chem 67:1357-1360 (1995).
- Ellis JP, Gray A, Richards F: Oculocutaneous albinism and bruising in two sisters Probable Hermansky-Pudlak syndrome. J R Soc Med 88:P293-P294 (1995).
- Falikborenstein TC, Holmes SA, Borochowitz Z, Levin A, Rosenmann A, Spritz RA: DNA-based carrier detection and prenatal diagnosis of tyrosinase-negative oculocutaneous albinism (OCA1A). Prenat Diagn 15:345-349 (1995).
 - Ferry WL, Hustad CM, Swing DA, Jenkins NA, Copeland NG: A transgenic mouse assay for agouti protein activity. Genetics 140:267-274 (1995).
 - Funayama M, Arakawa H, Yamamoto R, Nishino T, Shin T, Murao S: Effects of α and β -arbutin on activity of tyrosinases from mushroom and mouse melanoma. Biosci Biotechnol Biochem 59:143-144 (1995).
 - Gross A, Kunze J, Maier RF, Stoltenburgdidinger G, Grimmer I, Obladen R: Autosomal-recessive neural crest syndrome with albinism, black lock, cell migration disorder of the neurocytes of the gut, and deafness: ABCD syndrome. Am J Med Genet 56:322-326 (1995).
 - Hu XY, Leng ZZ: Determination of cyanide using a tyrosinase amperometric biosensor with catechol as substrate. Analyst 120:1555-1557 (1995).
 - Hustad CM, Perry WL, Siracusa LD, Rasberry C, Cobb L, Cattanach BM, Kovatch R, Copeland NG, Jenkins NA: Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. Genetics 140:255-265 (1995).
 - Jimenez-Cervantes C, Garcia-Borron JC, Lozano JA, Solano F: Effect of detergents and endogenous lipids on the activity and properties of tyrosinase and its related proteins. Bba-Gen Subjects 1243:421-430 (1995).
- Klebig ML, Wilkinson JE, Geisler JG, Woychik RP: Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci USA 92:4728-4732 (1995).
- Lee ST, Nicholls RD, Jong MTC, Fukai K, Spritz RA: Organization and sequence of the human P gene and identification of a new family of transport proteins. Genomics 26:354-363 (1995).
- Lookingbill DP, Lookingbill GL, Leppard B: Actinic damage and skin cancer in albinos in northern Tanzania: Findings in 164 patients enrolled in an outreach skin care program. J Am Acad Dermatol 32:653-658 (1995).
- Manne J, Argeson AC, Siracusa LD: Mechanisms for the pleiotropic effects of the agouti gene. Proc Natl Acad Sci USA 92:4721-4724 (1995).
- Miura I, Okumoto H, Makino K, Nakata A, Nishioka M: Analysis of the tyrosinase gene of the Japanese pond frog, *Kana nigromaculata*: Cloning and nucleotide sequence of the genomic DNA containing the tyrosinase gene and its flanking regions. Jpn J Genet 70:79-92 (1995).
- Reish O, Townsend D, Berry SA, Tsai MY, King RA: Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: The mechanism for reversible hypopigmentation in homocystinuria due to cystathionine βsynthase deficiency. Am J Hum Genet 57:127-132 (1995).
 - Schiaffino MV, Bassi MT, Rugarli EI, Renieri A, Galli L, Ballabio A: Cloning of a human homologue of the *Xenopus laevis* APX gene from the ocular albinism type 1 critical region. Hum Mol Genet 4:373-382 (1995).
 - Schnur RE, Wick PA: Intragenic TaqI restriction fragment length polymorphism (RFLP) in ClCN4, between the loci for X-linked ocular albinism (OA1) and microphthalmia with linear skin defects syndrome (MLS). Hum Genet 95:594-595 (1995).
 - Siracusa LD, Washburn LL, Swing DA, Argeson AC, Jenkins NA, Copeland NG: Hypervariable yellow (A^{hvy}), a new murine agouti mutation: A^{hvy} displays the largest variation in coat color phenotypes of all known agouti alleles. J Hered 86:121-128 (1995).

----- 26 -----

- Spritz RA, Fukai K, Holmes SA, Luande J: Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). Am J Hum Genet 56:1320-1323 (1995).
 - Visseren MJW, Vanelsas A, Vandervoort EIH, Ressing ME, Kast WM, Schrier PI, Melief CJM: CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991-3998 (1995).
 - Wang J, Chen QA: Microfabricated phenol biosensors based on screen printing of tyrosinase containing carbon ink. Anal Lett 28:1131-1142 (1995).
 - Ward KA, Moss C, Sanders DSA: Human piebaldism: Relationship between phenotype and site of kit gene mutation. Br J Dermatol 132:929-935 (1995).
 - Zemel MB, Kim JH, Woychik RP, Michaud EJ, Kadwell SH, Patel IR, Wilkison WO: Agouti regulation of intracellular calcium: Role in the insulin resistance of viable yellow mice. Proc Natl Acad Sci USA 92:4733-4737 (1995).

MISCELLANEOUS

Cinalli G: Melanotic neuroectodermal skull tumor. J Neurosurg 82:910(1995).

- Conlee JW, Bennett ML, Creel DJ: Differential effects of gentamicin on the distribution of cochlear function in albino and pigmented guinea pigs. Acta Oto-Laryngol 115:367-374 (1995).
- George JC, Edwards MK, Jakački RI, Khoduffin J: Melanotic neuroectodermal tumor of infancy. Amer J Neuroradiol 16:1273-1275 (1995).
- Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young LHY: Photodynamic therapy of pigmented choroidal melanomas. Invest Ophthalmol Visual Sci 36:871-878 (1995).
- Haddad G, Haddad JG, Kaplan FS: Severe symptomatic osteopenia in a man with pigmented micronodular adrenal hyperplasia. Clin Orthop 220-223 (1995).
- Hoshino S, Takahashi H: Melanotic neuroectodermal skull tumor Response. J Neurosurg 82:910-911 (1995).
- Martha GN, Milos NC: Confrontation of developing melanophore bars of dark and white axolotls with endogenous dark-embryo mannose-binding lectin correlates with melanophore bar disruption. Pigm Cell Res 8:66-74 (1995).
- McLean DI, Gallagher RP: "Sunburn" freckles, cafe-au-lait macules, and other pigmented lesions of schoolchildren: The Vancouver Mole Study. J Am Acad Dermatol 32:565-570 (1995).
- Sahn EE, Grine RC: A pigmented paraspinal plaque in an infant Congenital smooth-muscle hamartoma. Arch Dermatol 131:609(1995).
- Vinores SA, Henderer JD, Mahlow J, Chiu C, Derevjanik NL, Larochelle W, Csaky C, Campochiaro PA: Isoforms of platelet-derived growth factor and its receptors in epiretinal membranes: Immunolocalization to retinal pigmented epithelial cells. Exp Eye Res 60:607-619 (1995).